2,2-Difluorodeoxyuridine (BioDeep_00000397745)

   


代谢物信息卡片


2,2-Difluoro-2-deoxyuridine

化学式: C9H10F2N2O5 (264.0557754)
中文名称: 2,2-二氟-2-脱氧尿苷
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)(F)F
InChI: InChI=1S/C9H10F2N2O5/c10-9(11)6(16)4(3-14)18-7(9)13-2-1-5(15)12-8(13)17/h1-2,4,6-7,14,16H,3H2,(H,12,15,17)/t4-,6-,7-/m1/s1

描述信息

CONFIDENCE standard compound; EAWAG_UCHEM_ID 2649
2′,2′-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2′,2′-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro[1].

同义名列表

5 个代谢物同义名

2,2-Difluoro-2-deoxyuridine; 2,2-Difluorodeoxyuridine; dFdU; 2',2'-Difluoro-2'-deoxyuridine; 2′,2′-Difluorodeoxyuridine



数据库引用编号

25 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Bo Zhong, Elizabeth G Gibson, Abi Davis, Martine F Roussel, Clinton F Stewart. LC-MS/MS method for quantitation of gemcitabine and its metabolite 2',2'-difluoro-2'-deoxyuridine in mouse plasma and brain tissue: Application to a preclinical pharmacokinetic study. Journal of pharmaceutical and biomedical analysis. 2021 May; 198(?):114025. doi: 10.1016/j.jpba.2021.114025. [PMID: 33744463]
  • Lei Yin, Tianming Ren, Shiying Zhao, Meiyun Shi, Jingkai Gu. Comparative pharmacokinetic study of PEGylated gemcitabine and gemcitabine in rats by LC-MS/MS coupled with pre-column derivatization and MSALL technique. Talanta. 2020 Jan; 206(?):120184. doi: 10.1016/j.talanta.2019.120184. [PMID: 31514844]
  • Abeer F Alharbi, Robert A Kratzke, Jonathan D'Cunha, Michael Anthony Maddaus, Kinjal Sanghavi, Mark N Kirstein. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. Cancer chemotherapy and pharmacology. 2019 02; 83(2):387-391. doi: 10.1007/s00280-018-3757-7. [PMID: 30542769]
  • Ellen J B Derissen, Alwin D R Huitema, Hilde Rosing, Jan H M Schellens, Jos H Beijnen. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides. British journal of clinical pharmacology. 2018 06; 84(6):1279-1289. doi: 10.1111/bcp.13557. [PMID: 29451684]
  • Yilin Sun, Le Zhen, Ying Peng, Jiankun Wang, Fei Fei, Lixiang Aa, Wenjiao Jiang, Xue Pei, Li Lu, Jie Liu, Guangji Wang, Kun Hao. Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2018 May; 1084(?):4-13. doi: 10.1016/j.jchromb.2018.03.025. [PMID: 29558739]
  • M van Nuland, M J X Hillebrand, H Rosing, J A Burgers, J H M Schellens, J H Beijnen. Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial. Journal of pharmaceutical and biomedical analysis. 2018 Mar; 151(?):25-31. doi: 10.1016/j.jpba.2017.12.048. [PMID: 29294409]
  • Tormod Bjånes, Tina Kamčeva, Torunn Eide, Bettina Riedel, Jan Schjøtt, Asbjørn Svardal. Preanalytical Stability of Gemcitabine and its Metabolite 2', 2'-Difluoro-2'-Deoxyuridine in Whole Blood-Assessed by Liquid Chromatography Tandem Mass Spectrometry. Journal of pharmaceutical sciences. 2015 Dec; 104(12):4427-4432. doi: 10.1002/jps.24638. [PMID: 26372902]
  • Enaksha R Wickremsinhe, Lisa B Lee, Chris A Schmalz, John Torchia, Kenneth J Ruterbories. High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2013 Aug; 932(?):117-22. doi: 10.1016/j.jchromb.2013.06.008. [PMID: 23831704]
  • Lucy S Hodge, Levi S Downs, Justin C Chura, Sajeena G Thomas, Patrick S Callery, A Patrick Soisson, Paul Kramer, Stephen S Wolfe, Timothy S Tracy. Localized delivery of chemotherapy to the cervix for radiosensitization. Gynecologic oncology. 2012 Oct; 127(1):121-5. doi: 10.1016/j.ygyno.2012.07.097. [PMID: 22796462]
  • A Ramón-López, V Escudero-Ortiz, M J Duart-Duart, J J Pérez-Ruixo, B Valenzuela. [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2012 Jul; 36(4):194-206. doi: 10.1016/j.farma.2011.04.002. [PMID: 22078546]
  • P Specenier, G Guetens, J Dyck, G De Boeck, J Weyler, D Van den Weyngaert, K Aelbrecht, J B Vermorken. Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients. Cancer chemotherapy and pharmacology. 2011 Jul; 68(1):185-91. doi: 10.1007/s00280-010-1471-1. [PMID: 20882386]
  • L S Hodge, M E Taub, T S Tracy. Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells. Biochemical pharmacology. 2011 Apr; 81(7):950-6. doi: 10.1016/j.bcp.2011.01.016. [PMID: 21291869]
  • Emiko Sugiyama, Nahoko Kaniwa, Su-Ryang Kim, Ryuichi Hasegawa, Yoshiro Saito, Hideki Ueno, Takuji Okusaka, Masafumi Ikeda, Chigusa Morizane, Shunsuke Kondo, Noboru Yamamoto, Tomohide Tamura, Junji Furuse, Hiroshi Ishii, Teruhiko Yoshida, Nagahiro Saijo, Jun-Ichi Sawada. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clinical pharmacokinetics. 2010 Aug; 49(8):549-58. doi: 10.2165/11532970-000000000-00000. [PMID: 20608756]
  • Jan Gerard Maring, Floris M Wachters, Monique Slijfer, J Marina Maurer, H Marike Boezen, Donald R A Uges, Elisabeth G E de Vries, Harry J M Groen. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. European journal of clinical pharmacology. 2010 Jun; 66(6):611-7. doi: 10.1007/s00228-010-0799-0. [PMID: 20213492]
  • Jan Gerard Maring, Floris M Wachters, Marina Maurer, Donald R A Uges, Elisabeth G E de Vries, Harry J M Groen. Gemcitabine and epirubicin plasma concentration-related excretion in saliva in patients with non-small cell lung cancer. Therapeutic drug monitoring. 2010 Jun; 32(3):364-8. doi: 10.1097/ftd.0b013e3181d631a6. [PMID: 20335827]
  • Massimo Maffezzini, Fabio Campodonico, Matteo Puntoni, Antonietta Martelli, Francesca Mattioli. Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer. Urology. 2009 Nov; 74(5):1078-83. doi: 10.1016/j.urology.2009.05.094. [PMID: 19773039]
  • Chester Bowen, Sherry Wang, Hermes Licea-Perez. Development of a sensitive and selective LC-MS/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009 Jul; 877(22):2123-9. doi: 10.1016/j.jchromb.2009.06.002. [PMID: 19546035]
  • David Weissbrodt, Lubomira Kovalova, Christoph Ort, Vinitha Pazhepurackel, Ruedi Moser, Juliane Hollender, Hansruedi Siegrist, Christa S Mcardell. Mass flows of X-ray contrast media and cytostatics in hospital wastewater. Environmental science & technology. 2009 Jul; 43(13):4810-7. doi: 10.1021/es8036725. [PMID: 19673269]
  • Andrea Kuemmerle, Laurent A Decosterd, Thierry Buclin, Danielle Liénard, Roger Stupp, Pierre-Guy Chassot, François Mosimann, Ferdy Lejeune. A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. Cancer chemotherapy and pharmacology. 2009 Jan; 63(2):331-41. doi: 10.1007/s00280-008-0743-5. [PMID: 18587581]
  • Alessandra Felici, Susanna Di Segni, Michele Milella, Simona Colantonio, Isabella Sperduti, Barbara Nuvoli, Michela Contestabile, Andrea Sacconi, Massimo Zaratti, Gennaro Citro, Francesco Cognetti. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function. Clinical pharmacokinetics. 2009; 48(2):131-41. doi: 10.2165/00003088-200948020-00005. [PMID: 19271785]
  • Lai-San Tham, Ling-Zhi Wang, Ross A Soo, How-Sung Lee, Soo-Chin Lee, Boon-Cher Goh, Nicholas H G Holford. Does saturable formation of gemcitabine triphosphate occur in patients?. Cancer chemotherapy and pharmacology. 2008 Dec; 63(1):55-64. doi: 10.1007/s00280-008-0707-9. [PMID: 18305939]
  • Stephan A Veltkamp, Dick Pluim, Maria A J van Eijndhoven, Maria J Bolijn, Felix H G Ong, Rajgopal Govindarajan, Jashvant D Unadkat, Jos H Beijnen, Jan H M Schellens. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Molecular cancer therapeutics. 2008 Aug; 7(8):2415-25. doi: 10.1158/1535-7163.mct-08-0137. [PMID: 18723487]
  • Stephan A Veltkamp, Dick Pluim, Olaf van Tellingen, Jos H Beijnen, Jan H M Schellens. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug metabolism and disposition: the biological fate of chemicals. 2008 Aug; 36(8):1606-15. doi: 10.1124/dmd.108.021048. [PMID: 18490432]
  • Lai-San Tham, Lingzhi Wang, Ross A Soo, Soo-Chin Lee, How-Sung Lee, Wei-Peng Yong, Boon-Cher Goh, Nicholas H G Holford. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Jul; 14(13):4213-8. doi: 10.1158/1078-0432.ccr-07-4754. [PMID: 18594002]
  • Ronald J Bernardi, Lisa Bomgaars, Elizabeth Fox, Frank M Balis, Merrill J Egorin, Theodore F Lagattuta, Alberta Aikin, Patricia Whitcomb, Jamie Renbarger, Frank S Lieberman, Stacey L Berg, Susan M Blaney. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer chemotherapy and pharmacology. 2008 Jul; 62(2):355-61. doi: 10.1007/s00280-007-0601-x. [PMID: 17909804]
  • Stephan A Veltkamp, Robert S Jansen, Sophie Callies, Dick Pluim, Carla M Visseren-Grul, Hilde Rosing, Susanne Kloeker-Rhoades, Valerie A M Andre, Jos H Beijnen, Christopher A Slapak, Jan H M Schellens. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Jun; 14(11):3477-86. doi: 10.1158/1078-0432.ccr-07-4521. [PMID: 18519780]
  • Naoya Masumori, Yasuharu Kunishima, Megumi Hirobe, Motoi Takeuchi, Akio Takayanagi, Taiji Tsukamoto, Tatsuya Itoh. Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. Japanese journal of clinical oncology. 2008 Mar; 38(3):182-5. doi: 10.1093/jjco/hym171. [PMID: 18270381]
  • Stephan A Veltkamp, Jos H Beijnen, Jan H M Schellens. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. The oncologist. 2008 Mar; 13(3):261-76. doi: 10.1634/theoncologist.2007-0215. [PMID: 18378536]
  • Elena Marangon, Federica Sala, Orazio Caffo, Enzo Galligioni, Maurizio D'Incalci, Massimo Zucchetti. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry. Journal of mass spectrometry : JMS. 2008 Feb; 43(2):216-23. doi: 10.1002/jms.1293. [PMID: 17941128]
  • Fabio Campodonico, Francesca Mattioli, Valeria Manfredi, Giacomo Capponi, Paolo Pasquini, Antonietta Martelli, Massimo Maffezzini. Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer. Anticancer research. 2007 Mar; 27(2):1179-83. doi: NULL. [PMID: 17465260]
  • Emiko Sugiyama, Nahoko Kaniwa, Su-Ryang Kim, Ruri Kikura-Hanajiri, Ryuichi Hasegawa, Keiko Maekawa, Yoshiro Saito, Shogo Ozawa, Jun-ichi Sawada, Naoyuki Kamatani, Junji Furuse, Hiroshi Ishii, Teruhiko Yoshida, Hideki Ueno, Takuji Okusaka, Nagahiro Saijo. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Jan; 25(1):32-42. doi: 10.1200/jco.2006.06.7405. [PMID: 17194903]
  • Liia D Vainchtein, Hilde Rosing, Bas Thijssen, Jan H M Schellens, Jos H Beijnen. Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. Rapid communications in mass spectrometry : RCM. 2007; 21(14):2312-22. doi: 10.1002/rcm.3096. [PMID: 17577879]
  • S A Veltkamp, M J X Hillebrand, H Rosing, R S Jansen, E R Wickremsinhe, E J Perkins, J H M Schellens, J H Beijnen. Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Journal of mass spectrometry : JMS. 2006 Dec; 41(12):1633-42. doi: 10.1002/jms.1133. [PMID: 17117372]
  • Francesco Castelli, Maria Grazia Sarpietro, Maurizio Ceruti, Flavio Rocco, Luigi Cattel. Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. Molecular pharmaceutics. 2006 Nov; 3(6):737-44. doi: 10.1021/mp060059y. [PMID: 17140261]
  • Bea Pauwels, Annelies E C Korst, Hilde A J Lambrechts, Greet G O Pattyn, Christel M J de Pooter, Filip Lardon, Jan B Vermorken. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer chemotherapy and pharmacology. 2006 Aug; 58(2):219-28. doi: 10.1007/s00280-005-0158-5. [PMID: 16331496]
  • A López-Pousa, R Losa, J Martín, J Maurel, J Fra, M Sierra, A Casado, J García Del Muro, A Poveda, C Balañá, J Martínez-Trufero, E Esteban, J M Buesa. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. British journal of cancer. 2006 Jun; 94(12):1797-802. doi: 10.1038/sj.bjc.6603187. [PMID: 16721358]
  • Mark N Kirstein, Iman Hassan, Dan E Guire, Dennis R Weller, Jason W Dagit, James E Fisher, Rory P Remmel. High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 May; 835(1-2):136-42. doi: 10.1016/j.jchromb.2006.03.023. [PMID: 16584929]
  • K J Freise, T Martín-Jiménez. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. Journal of veterinary pharmacology and therapeutics. 2006 Apr; 29(2):137-45. doi: 10.1111/j.1365-2885.2006.00725.x. [PMID: 16515668]
  • K J Freise, T Martín-Jiménez. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. Journal of veterinary pharmacology and therapeutics. 2006 Apr; 29(2):147-52. doi: 10.1111/j.1365-2885.2006.00726.x. [PMID: 16515669]
  • Jeany M Rademaker-Lakhai, Mirjam Crul, Dick Pluim, Rolf W Sparidans, Paul Baas, Jos H Beijnen, Nico van Zandwijk, Jan H M Schellens. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Anti-cancer drugs. 2005 Oct; 16(9):1029-36. doi: 10.1097/01.cad.0000176507.78928.4d. [PMID: 16162981]
  • Francesca Mattioli, Antonio Curotto, Valeria Manfredi, Marzia Gosmar, Claudia Garbero, Carlo Ambruosi, Giorgio Carmignani, Antonietta Martelli. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. Anticancer research. 2005 May; 25(3c):2493-6. doi: NULL. [PMID: 16080482]
  • Kan Yonemori, Hideki Ueno, Takuji Okusaka, Noboru Yamamoto, Masafumi Ikeda, Nagahiro Saijo, Teruhiko Yoshida, Hiroshi Ishii, Junji Furuse, Emiko Sugiyama, Su-Ryang Kim, Ruri Kikura-Hanajiri, Ryuichi Hasegawa, Yoshiro Saito, Shogo Ozawa, Nahoko Kaniwa, Jun-Ichi Sawada. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Apr; 11(7):2620-4. doi: 10.1158/1078-0432.ccr-04-1497. [PMID: 15814642]
  • Ali I Shamseddine, Mohammad J Khalifeh, Fadi H Mourad, Aref A Chehal, Aghiad Al-Kutoubi, Jaber Abbas, Mohammad Z Habbal, Lida A Malaeb, Anwar B Bikhazi. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. Clinical pharmacokinetics. 2005; 44(9):957-67. doi: 10.2165/00003088-200544090-00005. [PMID: 16122282]
  • Maria Laura Immordino, Paola Brusa, Flavio Rocco, Silvia Arpicco, Maurizio Ceruti, Luigi Cattel. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. Journal of controlled release : official journal of the Controlled Release Society. 2004 Dec; 100(3):331-46. doi: 10.1016/j.jconrel.2004.09.001. [PMID: 15567500]
  • Neng-ming Lin, Su Zeng, Sheng-lin Ma, Yun Fan, Hai-jun Zhong, Luo Fang. Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector. Acta pharmacologica Sinica. 2004 Dec; 25(12):1584-9. doi: NULL. [PMID: 15569401]
  • José M Buesa, Raquel Losa, Aida Fernández, Marta Sierra, Emilio Esteban, Angela Díaz, Antonio López-Pousa, Joaquín Fra. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer. 2004 Nov; 101(10):2261-9. doi: 10.1002/cncr.20612. [PMID: 15484216]
  • Bilal Yilmaz, Yücel Yaşar Kadioğlu, Yilmaz Aksoy. Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography. Analytical biochemistry. 2004 Sep; 332(2):234-7. doi: 10.1016/j.ab.2004.05.059. [PMID: 15325290]
  • Joel M Reid, Wenchun Qu, Stephanie L Safgren, Matthew M Ames, Mark D Krailo, Nita L Seibel, John Kuttesch, John Holcenberg. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Jun; 22(12):2445-51. doi: 10.1200/jco.2004.10.142. [PMID: 15197207]
  • E De Berardinis, G Antonini, G J Peters, W J Loves, K Van der Born, G Codacci-Pisanelli, F Di Silverio. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU international. 2004 Mar; 93(4):491-4. doi: 10.1111/j.1464-410x.2003.04656.x. [PMID: 15008715]
  • Cristina Sottani, Massimo Zucchetti, Marco Zaffaroni, Maurizio Bettinelli, Claudio Minoia. Validated procedure for simultaneous trace level determination of the anti-cancer agent gemcitabine and its metabolite in human urine by high-performance liquid chromatography with tandem mass spectrometry. Rapid communications in mass spectrometry : RCM. 2004; 18(10):1017-23. doi: 10.1002/rcm.1436. [PMID: 15150823]
  • Ling-Zhi Wang, Boon-Cher Goh, How-Sung Lee, Paul Noordhuis, Godefridus J Peters. An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography. Therapeutic drug monitoring. 2003 Oct; 25(5):552-7. doi: 10.1097/00007691-200310000-00003. [PMID: 14508377]
  • Alexander Kiani, Claus-Henning Köhne, Thorsten Franz, Jens Passauer, Thorsten Haufe, Peter Gross, Gerhard Ehninger, Eberhard Schleyer. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer chemotherapy and pharmacology. 2003 Mar; 51(3):266-70. doi: 10.1007/s00280-003-0574-3. [PMID: 12655447]
  • Bruce Keith, Yan Xu, Jean L Grem. Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Feb; 785(1):65-72. doi: 10.1016/s1570-0232(02)00859-0. [PMID: 12535839]
  • Menachem Laufer, Sakkaraiappan Ramalingam, Mark P Schoenberg, Mary Ellen Haisfield-Wolf, Eleanor G Zuhowski, Irene N Trueheart, Mario A Eisenberger, Ofer Nativ, Merrill J Egorin. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Feb; 21(4):697-703. doi: 10.1200/jco.2003.09.028. [PMID: 12586808]
  • Merrill J Egorin, Eleanor G Zuhowski, Cynthia M McCully, Susan M Blaney, Jody Z Kerr, Stacey L Berg, Frank M Balis. Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Jul; 8(7):2437-42. doi: NULL. [PMID: 12114450]
  • S Fogli, R Danesi, A Gennari, S Donati, P F Conte, M Del Tacca. Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2002 Jun; 13(6):919-27. doi: 10.1093/annonc/mdf164. [PMID: 12123338]
  • S Fogli, R Danesi, F De Braud, T De Pas, G Curigliano, G Giovannetti, M Del Tacca. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2001 Nov; 12(11):1553-9. doi: 10.1023/a:1013133415945. [PMID: 11822754]
  • B J Delauter, R K Ramanathan, M J Egorin, L L Stover, E G Zuhowski, W Plunkett, W C Zamboni. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. Pharmacotherapy. 2000 Oct; 20(10):1204-7. doi: 10.1592/phco.20.15.1204.34586. [PMID: 11034044]
  • H T Edzes, G J Peters, P Noordhuis, J B Vermorken. Determination of the antimetabolite Gemcitabine (2',2'-difluoro-2'-deoxycytidine) and of 2',2'-difluoro-2'-deoxyuridine by 19F nuclear magnetic resonance spectroscopy. Analytical biochemistry. 1993 Oct; 214(1):25-30. doi: 10.1006/abio.1993.1451. [PMID: 8250231]